| Literature DB >> 34828343 |
Bala Murali Krishna Vasamsetti1, Kyongmi Chon1, Juyeong Kim1, Jin-A Oh1, Chang-Young Yoon1, Hong-Hyun Park1.
Abstract
Organophosphate pesticides (OPPs) are one of the most widely used insecticides. OPPs exert their neurotoxic effects by inhibiting acetylcholine esterase (AChE). Most of the gross developmental abnormalities observed in OPP-treated fish, on the other hand, may not be explained solely by AChE inhibition. To understand the overall molecular mechanisms involved in OPP toxicity, we used the zebrafish (ZF) model. We exposed ZF embryos to an OPP, phosmet, for 96 h, and then analyzed developmental abnormalities and performed whole transcriptome analysis. Phenotypic abnormalities, such as bradycardia, spine curvature, and growth retardation, were observed in phosmet-treated ZF (PTZF). Whole transcriptome analysis revealed 2190 differentially expressed genes (DEGs), with 822 and 1368 significantly up-and downregulated genes, respectively. System process and sensory and visual perception were among the top biological pathways affected by phosmet toxicity. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed significant enrichment of metabolic pathways, calcium signaling pathway, regulation of actin cytoskeleton, cardiac muscle contraction, drug metabolism-other enzymes, and phototransduction. Quantitative real-time PCR results of six DEGs agreed with the sequencing data expression profile trend. Our findings provide insights into the consequences of phosmet exposure in ZF, as well as an estimate of the potential risk of OPPs to off-target species.Entities:
Keywords: pesticide toxicity; phosmet; transcriptome analysis; zebrafish
Mesh:
Substances:
Year: 2021 PMID: 34828343 PMCID: PMC8624534 DOI: 10.3390/genes12111738
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096
Figure 1Representative images showing phosmet-induced deformities: (A) 24 hpf (upper panel) and 48 hpf (lower panel); (B) 72 hpf (left side panel) and 96 hpf (right side panel). Red dotted circles, abnormal somites; yellow dotted circles, abnormal eye formation or reduced retinal pigmentation; red arrow, malformed tails; white arrow, pericardial edema; yellow arrow, spine curvature; green dotted circle, unhatched embryos. NTZF, non-treated zebrafish; PTZF, phosmet-treated zebrafish. Scale = 1.0 mm.
Percentage of deformities observed at 24, 48, 72, and 96 h after phosmet treatment.
| Time | Deformity (%) | NTZF | PTZF |
|---|---|---|---|
| 24 hpf | Mortality | 0 | 17.50 ± 2.89 * |
| Edema symptoms | 2.50 ± 1.44 | 19.54 ± 7.11 * | |
| Abnormal somites | 2.50 ± 1.25 | 69.76 ± 8.02 * | |
| 48 hpf | Mortality | 0 | 32.50 ± 2.89 * |
| Low retina pigment | 0 | 63.07 ± 8.99 * | |
| Abnormal tail blood flow | 1.25 ± 1.25 | 53.85 ± 7.97 * | |
| Hyperemia | 0 | 44.22 ± 10.84 * | |
| 72 hpf | Mortality | 2.50 ± 1.44 | 43.75 ± 6.29 * |
| Unhatched embryos | 1.25 ± 1.25 | 78.22 ± 6.05 * | |
| Pericardial edema | 3.88 ± 1.30 | 61.63 ± 11.05 * | |
| Yolk sac edema | 2.57 ± 1.48 | 48.11 ± 9.31 * | |
| 96 hpf | Mortality | 2.50 ± 1.44 | 52.50 ± 3.23 * |
| Unhatched embryos | 0 | 82.29 ± 8.01 * | |
| Body curvature | 0 | 80.21 ± 5.15 * | |
| VMER | 25.00 ± 5.00 | 100.00 * | |
| TEER | 10.00 ± 5.77 | 90.00 ± 5.77 * |
Data are presented as the mean ± SD of four 24-well plates (20 embryos/plate) collected from two different experiments. Statistical significance was evaluated using an unpaired Student’s t-test. * Statistically significant (p < 0.005). NTZF, non-treated zebrafish; PTZF, phosmet-treated zebrafish; VMER, vision-mediated escape response; TEER, touch-evoked escape response. VEER and TEER data are presented as the mean ± SD of three experiments (10 embryos/experiment).
Figure 2Average heartbeats per minute at 48, 72, and 96 hpf. NTZF, non-treated zebrafish; PTZF, phosmet-treated zebrafish. The results are mean ± SD (n = 3). Statistical significance was evaluated using an unpaired t-test. * (p < 0.0001).
Figure 3The graph represents the average body length at 144 hpf. Representative images show the body length at 144 hpf. NTZF, non-treated zebrafish; PTZF, phosmet-treated zebrafish. Scale = 1.0 mm. The results are mean ± SD (n = 4). Statistical significance was evaluated using an unpaired t-test. * (p < 0.001).
Summary of sequence data generated for the transcriptome and quality filtering.
| Samples | Total Reads | Clean Reads | Mapped Reads | Mapped Rate (%) | Q20 (%) | Q30 (%) | GC (%) |
|---|---|---|---|---|---|---|---|
| NTZF-1 | 72,783,012 | 71,783,716 | 60,458,452 | 84.22 | 98.91 | 96.05 | 43.62 |
| NTZF-2 | 61,925,392 | 60,857,682 | 51,896,692 | 85.28 | 98.91 | 96.06 | 44.95 |
| NTZF-3 | 60,878,020 | 59,726,314 | 51,603,485 | 86.4 | 98.85 | 95.87 | 46.00 |
| PTZF-1 | 69,410,088 | 68,273,094 | 45,753,478 | 67.02 | 98.89 | 96.11 | 53.24 |
| PTZF-2 | 66,557,046 | 65,493,004 | 55,524,220 | 84.78 | 98.92 | 96.13 | 49.44 |
| PTZF-3 | 74,253,266 | 73,041,798 | 61,232,206 | 83.83 | 98.97 | 96.27 | 47.69 |
NTZF, non-treated zebrafish; PTZF, phosmet-treated zebrafish; Q20, Phred quality score 20; Q30, Phred quality score 30; GC, guanine–cytosine.
Figure 4(A) The volcano plot for differentially expressed genes (DEGs) of phosmet-treated compared and non-treated zebrafish (NTZF). Individual colored dots indicate upregulated (yellow, FDR < 0.05 and FC ≥ 2) and downregulated (blue, FDR < 0.05 and FC ≤ −2) genes in the phosmet-treated group; (B) heat map of differential expression in NTZF vs. PTZF. Heat map of one-way hierarchical clustering using the Z-score for normalized values (log2 based).
Figure 5Top 10 enriched functional gene ontology terms in biological process (BP) (A), cellular component (CC) (B), and molecular function (MF) (C) of differentially expressed genes.
Figure 6Top 10 KEGG pathways in phosmet-treated zebrafish compared with non-treated zebrafish.
A summary of KEGG pathway analysis for differentially expressed genes.
| Term | Genes | FDR | |
|---|---|---|---|
| Metabolic pathways | gls2a, gls2b, gpx9, gda, hacd1, chia.2, gyg1b, tecrl2b, zgc:153896, elovl4b, zgc:153704, cyp7a1, zgc:103586, pgam2, pde6g, lpin1, ATP8, aoc1, LOC559107, ndufa4l2a, zgc:109982, pts, tyr, si:ch211-214p16.3, gch2, ampd1, mdh1ab, ND4L, tecrl2a, dhrs3a, atpv0e2, agxta, chs1, cyp21a2, aldoab, gal3st1a, ckmt2b, th2, si:dkey-78a14.5, dpm3, spam1, csgalnact1b, nat8l, ptges, atp5ia, nme2a, ND1, ND3, ND5, gpx8, ND2, si:dkey-78a14.4, aanat2, ndufa1, adssl1, si:ch211-217a12.1, ATP6, entpd8, alpi.2, tymp, ndufa4, elovl8a, entpd5a, zgc:112320, pigw, haao, CYTB, ckma, cel.1, gstk4, hao2, nme2b.2, pigh, pfkma, hpda, pnp4b, ND4, aldh3b2, smyd1a, b3gnt5a, mocs1, uox, st3gal7, si:ch211-106j24.1, pde6c, ndufa2, ugt5e1, fhit, sdhdb, acot19, agxtb, cyp2r1, COX3, COX1, COX2, tyrp1b, pde6d, acp5a *, sgpp2 *, galnt6 *, pik3c2g *, gal3st1b *, ugt5a1 *, atic *, glulc *, sqlea *, alp3 *, aldh3b1 *, p4ha1b *, paics *, elovl6l *, ethe1 *, plcd1a *, zgc:100864 *, zgc:154054 *, ugt1a5 *, cmasb *, aldob *, gstm.3 *, cyp24a1 *, ugt1a7 *, cbr1l *, zgc:123275 *, fut9d *, zgc:112332 *, b4galnt3b *, hao1 *, ugt1a1 *, mthfd1l *, si:ch73-337l15.2 *, ugt5a4 *, ptgs2b *, cmbl *, mgst1.2 *, rdh12l *, dao.1 *, zgc:163121 *, nansb *, si:ch211-276a23.5 *, cox4i1l *, pla2g4f.1 *, ugt1a2 *, ugt1a6 *, cyp3a65 *, cyp17a1 *, alas2 *, ptgs2a *, bhmt *, sqrdl *, nqo1 *, LOC565422 *, ptgis *, gstp1 *, ugt2a4 *, gstp2 * | 1.14402 × 10−53 | 1.61306 × 10−51 |
| Calcium signaling pathway | slc25a4, adrb2b, atp2a1l, mylk4b, stim2a, mylk4a, camk1gb, fgf4, ednraa, casq1a, trdn, tnnc2, p2rx5, avpr1aa, p2rx8, si:rp71-17i16.4, cacna1sb, casq2, calm1b, egf, ednrba, zgc:56235, casq1b, orai1a, si:dkey-247m21.3, fgf1a, p2rx3a, ryr3, atp2a1, phkg1b, tacr3a *, mcoln3a *, plcd1a *, p2rx1 *, si:dkey-251i10.1 *, cxcr4a *, ltb4r2a *, gna15.1 *, gna14 * | 2.39485 × 10−15 | 1.68837 × 10−13 |
| Phototransduction | opn1mw2, gngt1, opn1mw1, guca1c, gnat1, guca1d, pde6g, rhol, gnat2, rho, guca1e, rcvrnb, rcvrn2, grk7a, rcvrn3, calm1b, zgc:112320, cnga1 | 6.05641 × 10−15 | 2.84651 × 10−13 |
| Cardiac muscle contraction | atp2a1l, si:ch211-139a5.9, cacng6b, zgc:163073, zgc:86725, cacng1a, trdn, tnnt2d, atp1b1a, tpm4b, tnnt2e, cacna1sb, casq2, atp1b2b, CYTB, atp1a3b, atp1b4, smyhc1, atp2a1, atp1b2a, COX3, COX1, COX2, cox4i1l *, atp1a1a.2 * | 2.86244 × 10−14 | 1.00901 × 10−12 |
| Drug metabolism—other enzymes | zgc:103586, si:dkey-78a14.5, nme2a, si:dkey-78a14.4, gstk4, nme2b.2, aldh3b2, ugt5e1, ugt5a1 *, tpmt.1 *, tpmt.2 *, aldh3b1 *, ugt1a5 *, gstm.3 *, ugt1a7 *, ugt1a1 *, ugt5a4 *, mgst1.2 *, ugt1a2 *, ugt1a6 *, gstp1 *, ugt2a4 *, gstp2 * | 4.12652 × 10−13 | 1.16368 × 10−11 |
| Cell adhesion | cldn7a, cldn19, mpz, cldn5b, mag, si:ch211-286o17.1, cldnj, cdh15, itgb1a, cd99l2, cldnf, cdh1, cldnc, cldn8, itgb1b.1, oclnb, zgc:110333, cldn7b, cldnb, oclna, cldn1, cldne, si:ch211-95j8.5, cldni, zgc:136892 | 2.61473 × 10−12 | 6.14462 × 10−11 |
| Aminoacyl-tRNA | trnS2, trnA, trnH, trnD, trnE, trnG, trnK, trnN, trnM, trnY, trnP, trnQ, trnC, trnR, trnI, trnL1, trnS1 | 4.82031 × 10−12 | 9.70947 × 10−11 |
| Biosynthesis of | pts, gch2, dhrs3a, nme2a, adssl1, alpi.2, haao, nme2b.2, hpda, mocs1, ugt5e1, ugt5a1, alp3, ugt1a5, ugt1a7, zgc:112332, ugt1a1, mthfd1l, ugt5a4, rdh12l, ugt1a2, ugt1a6, alas2, nqo1, ugt2a4 | 2.2858 × 10−11 | 3.55548 × 10−10 |
| Metabolism of | gstk4, aldh3b2, ugt5e1, ugt5a1,aldh3b1, ugt1a5, gstm.3, ugt1a7, cbr1l, ugt1a1, ugt5a4, mgst1.2, ugt1a2, ugt1a6, gstp1, ugt2a4, gstp2 | 2.50462 × 10−11 | 3.55548 × 10−10 |
| Regulation of actin cytoskeleton | cfl2, cxcl12b, mylk4b, mylk4a, fgf4, mylpfb, cxcl12a, LOC101885790, si:dkey-44g17.6, itga10, egf, tmsb, scinla, pfn2l, itgb1a, fgf1a, si:ch73-116o1.2, brk1, itga2.2, itgb1b.1, cxcr4a, rac2, zgc:86896, myh9a, fn1b, itgb3a, gsnb, pfn1, cfl1l, zgc:101810 | 2.52162 ×10−11 | 3.55548 ×10−10 |
*: upregulated, normal text: downregulated, FDR: false discovery rate.
qPCR validation of randomly selected up- and downregulated genes detected in transcriptome data.
| Gene Symbol | Fold Change (RNA-Seq) | Fold Change (qPCR) |
|---|---|---|
|
| 6.13 | 4.17 ± 0.14 |
|
| 4.14 | 2.13 ± 0.21 |
|
| 12.09 | 5.15 ± 1.28 |
|
| −7.25 | −4.40 ± 0.56 |
|
| −2.07 | −2.84 ± 0.55 |
|
| −4.27 | −3.91 ± 1.02 |